Kourtney Harrington, MD
Internal Medicine · Bella Vista, ARNPI 1962762682
Payments from drug & device makers
Across 202 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$531
- GSK$445
- AbbVie$431
- Pfizer$349
- Astellas Pharma US Inc$279
- Novo Nordisk$202
- plus $833 from 19 others
What the payments were for
- Food & beverage$3,070100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $531 |
| GSK | 33 | $445 |
| AbbVie | 31 | $431 |
| Pfizer | 22 | $349 |
| Astellas Pharma US Inc | 16 | $279 |
| Novo Nordisk | 12 | $202 |
| Johnson & Johnson | 7 | $111 |
| Phathom Pharmaceuticals, Inc. | 7 | $100 |
| Lilly USA, LLC | 6 | $87 |
| AstraZeneca | 5 | $75 |
| Boehringer Ingelheim | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Bayer | 2 | $39 |
| Dynavax Technologies Corporation | 2 | $38 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $34 |
| Exact Sciences | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Merck | 2 | $29 |
| Irhythm Technologies, Inc. | 2 | $28 |
| Abbott | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Novartis | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$3,070 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $79,562 |
| OzempicSemaglutide | 62 | $73,888 |
| MounjaroTirzepatide | 55 | $68,451 |
| JardianceEmpagliflozin | 50 | $51,771 |
| ProliaDenosumab | 29 | $50,434 |
| Repatha SureclickEvolocumab | 57 | $35,915 |
| FarxigaDapagliflozin Propanediol | 37 | $27,842 |
| TrulicityDulaglutide | 14 | $22,327 |
| MyrbetriqMirabegron | 34 | $21,779 |
| RybelsusSemaglutide | 15 | $21,502 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,191 |
| XareltoRivaroxaban | 23 | $15,814 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $11,838 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,796 |
| LinzessLinaclotide | 15 | $8,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $202 | $95,39077 claims |
| Lilly USA, LLCMounjaro, Trulicity | $87 | $90,77869 claims |
| PfizerEliquis | $349 | $79,56299 claims |
| Boehringer IngelheimJardiance | $64 | $51,77150 claims |
| AmgenProlia | $531 | $50,43429 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $445 | $33,02946 claims |
| AstraZenecaFarxiga, Symbicort | $75 | $32,65049 claims |
| Astellas Pharma US IncMyrbetriq | $279 | $21,77934 claims |
| Johnson & JohnsonXarelto | $111 | $15,81423 claims |
| MerckBelsomra, Januvia | $29 | $14,49829 claims |
| AbbVieLinzess, Synthroid | $431 | $11,06959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Bella Vista
- David EstesBella Vista$11K
- Cara RileyBella Vista$6K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
- Kathleen GannonRogers$450K
- Alexander KaczenskiLittle Rock$305K
- John HendersonSearcy$102K
- David PyleJonesboro$93K
- Manisha SinghLittle Rock$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.